Lab managers seeking a streamlined path from bench research to clinical manufacturing can now rely on AMSBIO’s GMP-grade StemFit® for Differentiation. This medium is chemically defined, free of animal components, and now produced under strict GMP guidelines—addressing core requirements for clinical readiness.
StemFit® for Differentiation not only supports consistent cell outcomes, but also reduces regulatory hurdles and operational complexity. With predictable performance and cost-managed upgrades to GMP, lab managers can maintain efficiency while preparing for clinical translation.
Benefits for Lab Managers
- Consistent, reproducible results for improved lab workflows.
- GMP compliance aligns with regulatory standards.
- Animal-free formulation enhances safety and protocol stability.
- Ready for clinical manufacturing—no need for protocol changes.
- Affordable GMP transition supports budget-conscious labs.
With the full range of formulations converting to GMP by 2025, AMSBIO is empowering labs for scalable and compliant operations.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. The original press release was provided by AMSBIO.
